Opened database successfully add two inverted commas for every one Medicine for Medical Students, Doctors, Physicians, Surgeons, Allied Healthcare Professionals

MEDICAL DISCLAIMER:The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd

Abciximab

About

Anaesthetics and Critical Care

Obstetrics Gynaecology

Trauma and Orthopaedics

Twitter

Urology

Version Jan 2023

ReoPro (abciximab) is indicated as an adjunct to percutaneous coronary intervention (PCI)

About: Always check the BNF link here

Antiplatelet agent used prior to PCI. Main risk is bleeding

Mode of action

Monoclonal antibody to platelet Glycoprotein IIbIIIa receptor
Prevents platelet aggregation
Rapid onset of action and a plasma half-life of c . 30 min.

Indications

Percutaneous Coronary Interventions e.g. angioplasty and stenting
Unstable angina awaiting PCI

Dose: Under specialist use only. See BNF or equivalent

Name	Starting Dose	Frequency	Route
Abciximab	250 mcg/kg over 1 minute	stat	IV
Abciximab	0.125 mcg/kg/min Infusion	IV Infusion	IV

Interactions

Caution with other antiplatelets or anticoagulants
Abciximab is eliminated from plasma by rapid binding to platelets but platelets may remain inhibited for 12-24 h because of persistent binding to the GPIIb/IIIa fibrinogen receptor

Contraindications

Suspected or Proven Bleeding, Recent stroke, AVM, Intracranial aneurysm
Recent major surgery/trauma, Hypertensive retinopathy
Where bleeding is likely, Severe Hypertension

Side effects

Bleeding, low platelets, Nausea, vomiting, hypotension
Chest pain, fever, pleurisy, ARDS, Tamponade
Haemorrhage : Monitor FBC and check baseline clotting and observations
Moderate thrombocytopenia

References

Summary Product Characteristics

PLEASE NOTE LEGAL ADVICE: The contents are under continuing development and improvements and may contain errors of omission or fact. The official launch will be at the end of 2018. Feedback vital and always welcome at drokane at gmail.com. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice. It is only for educational purposes. Please adhere to your local protocols. If you are unwell please seek healthcare advice from your doctor. This does not replace senior or specialist advice. If you do not accept this then please do not use the website. If you need medical advice, please consult a doctor or other appropriate medical professional. If you are a medical professional and you need advice then speak to your senior or colleagues.

Hits